September 4-7 2018
Boston, MA

Twitter logo for website footers 2

Focus Day

Post-Conference Focus Day Agenda

Friday, September 7th 2018

View Full Program Here to see full details on these sessions.

To attend post-conference focus day register here

Overcoming CAR-T Toxicity in Solid Tumors

Alternative CAR Strategies

9.00 Overcoming Manufacturing Challenges in Solid Tumors

– Explore manufacturing strategies to create a GMP-in-a-box process

– Methods to reduce footprint and increase throughput

– Discuss an easily transferrable process that would reduce variation between centers and make transfers seamless

Isabelle Riviera, Director, Cell Therapy & Cell Engineering Facility, Memorial Sloan Kettering Cancer Center

9.00 Developing Gamma-Delta CAR-T to Treat Cancer and Viral Disease

– Generating a tox-free CAR-T

– Pharmaceuticalization of gamma-delta T cell therapies

– Sustainable business models

Michael Leek, Executive, TC BioPharm

9.30 Manufacturing Spear T-Cells for Autologous Therapy of Solid Tumors

– SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells recognize HLA-restricted tumor antigens, and show clinical promise in exploratory trials

– Reliable manufacturing is key for early phase trials, and requires specialized supply chain, process development, and analytic strategies

– Process optimization can be explored in early phase trials, while reduced analytic testing and decreased process flexibility is required for mature products.

Mark Dudley, Senior Vice President of Bioprocessing, Adaptimmune

9.30 Future of Virus Specific T Cells in Oncology

– Redirecting antiviral immunity

– The VST as a platform for solid tumor cell therapy

– Clinical application of VST technology

– Rational combination therapy for next generation immunoncology

John Connolly, Chief Scientific Officer, Tessa Therapeutics

10.00 Panel Discussion: Strategies to Increase Efficacy of CAR-T in Solid Tumors

– Lack of unique tumor-associated antigen in most cancers

– Inefficient trafficking of CAR-T cells to tumor sites

– Presence of immunosuppressive molecules and cells

– Metabolically hostile tumor microenvironment

Miguel Forte, Chief Executive Officer, Zelluna Immunotherapy
Mario Marcondes, Medical Director, Clinical Development, Nektar Therapeutics
Charles Sentman, Professor of Microbiology and Immunology, Dartmouth Geisel School of Medicine

10.00 Panel discussion: Building Sustaining Business Models for CAR Therapies

– Explore different business strategies to reduce cost of goods

– Identify different models to make CAR therapies more commercially viable

– Discuss the opportunities in allogeneic CAR-T therapies

Michael Leek, Chief Executive, TC Biopharm
Jim Beitel, SVP, Corporate Development, Fate Therapeutics
Robert Hofmeister, Chief Scientific Officer, TCR2 Therapeutics

 11.00  Morning Refreshments & Networking

12.00 CAR T Cell Therapy for Glioblastoma: Progress, Promises and Challenges

– Optimizing CAR T Cell delivery into the brain

– Identifying barriers to CAR T cell responses in malignant brain tumors

– Future directions in enhancing CAR T cell therapy for glioblastoma

Behnam Badie, Professor and Chief, Division of Neurosurgery & Director, Brain Tumor Program, City of Hope Medical Center

12.00 Use of NKT Cells for The Development of off-the-shelf CAR Products Without The Need for Gene Editing

– Explore the use of NKT cells in allogeneic settings without the need for gene editing due to their invariant, targeting pathogen-specific glycolipids that are not found on human cells and therefore do not cause graft versus host disease

– Discuss the development of multiple products based on the CAR-NKT platform against indications of high unmet medical need, in very close partnership with the Baylor College of Medicine

– Explore the enhanced persistence and activity in solid tumors of Cell Medica’s products which are engineered to secrete cytokines

Stefanos Theoharis, SVP, Partnering and Corporate Development, Cell Medica

12.30 Claudin18.2-Targeted Car-T for the Treatment of Patients with Pancreatic Cancer or Gastric Cancer

– Development of Claudin18.2-targeted CAR-T cells

– The safety profile of claudin18.2  targeted CAR-T cells

– Efficacy of claudin18.2-targeted CAR-T cells

Zonghai Li, Founder, CEO and CSO, CARSgen Therapeutics

12.30 Developing Novel CAR-Macrophage Therapies for Solid Tumors

– Macrophage biology is ideally suited for solid tumors

– Explore the unique challenges in developing CAR-Macrophages to enhance efficacy in solid tumors

– Leveraging CAR-T production insights for supply chain

Steven Kelly, President and CEO, CARMA Therapeutics

1.00 Overcoming Safety Challenges of Genetically Engineered T-Cell Therapy for the Treatment of Cancer

– Safety challenges such as CRS and neurotoxicity are widely observed in T-cell therapy treatments, Eureka developed its proprietary ARTEMIS™ platform to tackle the problem

– In-vitro and mouse in-vivo data has shown robust and specific killing activity of our leading programs: ET190L1- ARTEMIS™ and ET1402L1- ARTEMIS™

– Clinical experience of ARTEMIS™ platform-based T-cell therapy

Bijan Nejadnik, CMO, Eureka Therapeutics

1.00 CAR-T cells and Combination Therapies: The Next Chapter of the Immuno-Oncology Revolution

This talk will initially review general combination strategies for CAR-T therapies and will subsequently focus on Mustang Bio’s combination strategy for solid tumors

– The impressive results demonstrated by CAR-T therapies are driving interest in immunotherapy combinations that have a synergistic mechanism of action

– Combination strategies are a key area of clinical research and may unlock the potential of immune-oncology therapies by overcoming multiple mechanisms of immune evasion and targeting non-redundant pathways

Sadik Kassim, Chief Scientific Officer, Mustang Bio

1.30 Lunch & Networking

2.30 Deep PrimedTM Immunotherapy: Controlling The Tumor Microenvironment in T Cell Therapy

– Torque is developing Deep Primed™ cell therapies that direct and evoke immune responses in the tumor and immune microenvironment

– The Torque platform makes it possible to anchor powerful stimulatory cytokines, antibodies, and small molecules directly to immune cells to direct their activity and increase their efficacy and durability in the “hostile” tumor microenvironment, while controlling systemic exposure

– Torque’s lead product candidate is Deep IL-15, which is entering clinical development for hematologic and solid tumors

Thomas Andresen, Co-founder and CSO, Torque Therapeutics

2.30 Accessories for Your CAR: Combining Cells With Drug Therapy to Improve Outcomes

– Review anticipated outcomes with conventional CAR T cell therapy (primarily CLL/NHL)

– Rationale for combination therapy

– Discuss results of CAR T cells plus drugs therapies

check point inhibitors

– Discuss concerns regarding combinations (toxicity, GVHD, cost) and scheduling (when to start, duration of therapy, when to stop?)

David Porter, Director of Cell Therapy and Transplant, University of Pennsylvania

3.00 CAR19 T Cells Carrying Multi-Antigen Targeting Payloads: Tackling Persistence and Tumor Antigen Heterogeneity for the Treatment of Diverse Tumors
– IMPACTtm technology enables robust and modular antigen targeting using a single CAR- Multiple antigens are attacked simultaneous, with low pM activity- Technology addresses critical issues of antigen loss and antigen heterogeneity

Paul Rennert, President & CSO, Aleta Biotherapeutics

3.00 A Novel Approach Near Term to Optimize Current and Future CAR-T

– Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a key driver in CAR-Tinduced toxicities, particularly neurotoxicity, which remain a barrier to expanded use

– Studying lenzilumab, a novel monoclonal antibody that neutralizes circulating GM-CSF, to optimize current CAR-T by preventing or minimizing serious side effects and potentially boosting efficacy

– Establishing this mechanism also has the potential to expand CAR-T use, including aiding expansion into solid tumors and synergies with checkpoint inhibitors

Cameron Durrant, Chairman and Chief Executive Officer, Humanigen, Inc.

3.30 Close of Focus Day